Abiopharma

General Announcement: Monthly Return of Equity Issuer on Movements in Securities

Warrants Listing - Structured Warrants: Proposed Issue of Call Warrants

NiCE Exceeds Revenue Guidance Range, Reporting 8% Year-Over-Year Revenue Growth in Second Quarter 2026

General Announcement: Standard & Poors Ratings Publication on Singapore Post

Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s): Change in Interest of Substantial Unitholder - Temasek Holdings (Private) Limited

General Announcement: Appointment of Rajah and Tann Singapore LLP as Legal Adviser

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Changes in Interest of Director/Chief Executive Officer

General Announcement: Use Of Proceeds From the Equity Fund Raising

General Announcement: UPDATE ON STRATEGIC REVIEW

General Announcement: Clarification on Unaudited Interim Financial Statements as at 30 June 2026